… in the use of PARP inhibitors and novel therapies … patient. Despite advancements with PARP inhibitors in prostate cancer, … challenges that limit the optimal PARP inhibitor implementation. The primary … who may be eligible for PARP inhibitors. Although we…

… poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) and serine…

… this study. Exploiting vulnerabilities with PARP inhibitors The team also discovered … treatment display heightened sensitivity to PARP inhibitors (PARPi) – a class of … of opportunity for treatment with PARP inhibitors. Upfront combined inhibition with …

Pack your picnics, head for Shaw House and join Ratty, Mole, Badger, and the fantastically irrepressible Toad as they embark on the adventure of a lifetime culminating in a colourful battle to save Toad Hall from the mischievous weasels! Wind in the …

… -terminal poly (ADP-ribose) polymerase (PARP) active site, have been implicated … area. Given the role of PARP-related pathways in DNA damage …

… for predicting the efficacy of PARP inhibitors and selecting appropriate treatment … of insurance coverage for the PARP inhibitor “niraparib (Zejula in trademark …

… must have progressed on prior PARP inhibitor therapy. There were no …

… launch, Zejula (niraparib), is a PARP inhibitor indicated for advanced and …

… advancing DDR-targeted therapies, including PARP inhibitors, some of which have …

… is advancing a next-generation PARP inhibitor that represents a step … selectivity.  While four first-generation PARP inhibitors have achieved approval, they … hematologic toxicities.  "First-generation PARP inhibitors target both PARP1 and …